JP2007513959A - 抗ウイルス性薬学的組成物 - Google Patents
抗ウイルス性薬学的組成物 Download PDFInfo
- Publication number
- JP2007513959A JP2007513959A JP2006543955A JP2006543955A JP2007513959A JP 2007513959 A JP2007513959 A JP 2007513959A JP 2006543955 A JP2006543955 A JP 2006543955A JP 2006543955 A JP2006543955 A JP 2006543955A JP 2007513959 A JP2007513959 A JP 2007513959A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antiviral
- ionic
- zinc
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 141
- 239000008194 pharmaceutical composition Substances 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 244
- 229920006317 cationic polymer Polymers 0.000 claims abstract description 45
- 229920001661 Chitosan Polymers 0.000 claims abstract description 44
- 239000011701 zinc Substances 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 43
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 43
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 41
- 239000002184 metal Substances 0.000 claims abstract description 40
- 229910052751 metal Inorganic materials 0.000 claims abstract description 40
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960003872 benzethonium Drugs 0.000 claims abstract description 10
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052742 iron Inorganic materials 0.000 claims abstract description 10
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims abstract description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract 12
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 58
- 241000700605 Viruses Species 0.000 claims description 55
- 230000009385 viral infection Effects 0.000 claims description 44
- 208000036142 Viral infection Diseases 0.000 claims description 43
- 241000709661 Enterovirus Species 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000011592 zinc chloride Substances 0.000 claims description 29
- 235000005074 zinc chloride Nutrition 0.000 claims description 29
- 230000003612 virological effect Effects 0.000 claims description 27
- 239000000499 gel Substances 0.000 claims description 19
- 206010022000 influenza Diseases 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 241000701161 unidentified adenovirus Species 0.000 claims description 15
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- 241000712461 unidentified influenza virus Species 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 9
- 210000004392 genitalia Anatomy 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 201000009240 nasopharyngitis Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 6
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 5
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 208000003265 stomatitis Diseases 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 2
- 239000004922 lacquer Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 75
- 210000004027 cell Anatomy 0.000 description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 44
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical group [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 25
- 239000011780 sodium chloride Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- -1 pH adjusters Substances 0.000 description 16
- 238000010979 pH adjustment Methods 0.000 description 16
- 239000002245 particle Substances 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- 241000713196 Influenza B virus Species 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000003292 kidney cell Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000003443 antiviral agent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 239000005714 Chitosan hydrochloride Substances 0.000 description 6
- 208000001688 Herpes Genitalis Diseases 0.000 description 6
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 201000004946 genital herpes Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 231100000344 non-irritating Toxicity 0.000 description 6
- 210000001944 turbinate Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 206010061494 Rhinovirus infection Diseases 0.000 description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 229940097496 nasal spray Drugs 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- VVZBFOKBSDGVGZ-UHFFFAOYSA-N BENZALKONIUM Chemical compound CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 VVZBFOKBSDGVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 229920003149 Eudragit® E 100 Polymers 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940124274 edetate disodium Drugs 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 150000002736 metal compounds Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 150000003751 zinc Chemical class 0.000 description 3
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010060931 Adenovirus infection Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010073931 Genital herpes simplex Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001098650 Human rhinovirus A15 Species 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- OFBLZCXWVROESG-PKPIPKONSA-N (2s)-1,2,3-trihydroxyheptan-4-one Chemical compound CCCC(=O)C(O)[C@@H](O)CO OFBLZCXWVROESG-PKPIPKONSA-N 0.000 description 1
- PKMTWMDBJHRDBM-ODZAUARKSA-N (z)-but-2-enedioic acid;zinc Chemical compound [Zn].OC(=O)\C=C/C(O)=O PKMTWMDBJHRDBM-ODZAUARKSA-N 0.000 description 1
- UYHAERNXVVKSCT-PGUFJCEWSA-N 1,2-dipalmitoyl-sn-glycero-3-phosphoethanol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCCCCCCCCC UYHAERNXVVKSCT-PGUFJCEWSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- RUAUPNFNQOGIFF-UHFFFAOYSA-N 1-(4-tert-butyl-2,5-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC(C(C)(C)C)=C(OC)C=C1CC(C)N RUAUPNFNQOGIFF-UHFFFAOYSA-N 0.000 description 1
- HPQUMJNDQVOTAZ-UHFFFAOYSA-N 2,2-dihydroxypropanoic acid Chemical compound CC(O)(O)C(O)=O HPQUMJNDQVOTAZ-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010022005 Influenza viral infections Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- OZBDFBJXRJWNAV-UHFFFAOYSA-N Rimantadine hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(C(N)C)C3 OZBDFBJXRJWNAV-UHFFFAOYSA-N 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002128 anti-rhinoviral effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000008726 choto-san Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- JBBPTUVOZCXCSU-UHFFFAOYSA-L dipotassium;2',4',5',7'-tetrabromo-4,7-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [K+].[K+].O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 JBBPTUVOZCXCSU-UHFFFAOYSA-L 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- MFGZXPGKKJMZIY-UHFFFAOYSA-N ethyl 5-amino-1-(4-sulfamoylphenyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC=C(S(N)(=O)=O)C=C1 MFGZXPGKKJMZIY-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 229940028864 flumadine Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- QDUZQOIJXPPTLY-IYEMJOQQSA-N iron;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound [Fe].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QDUZQOIJXPPTLY-IYEMJOQQSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940100652 nasal gel Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- UPHWVVKYDQHTCF-UHFFFAOYSA-N octadecylazanium;acetate Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCCN UPHWVVKYDQHTCF-UHFFFAOYSA-N 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000471 pleconaril Drugs 0.000 description 1
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- TVOIPJPTFTYKQM-UHFFFAOYSA-N propanedioic acid;zinc Chemical compound [Zn].OC(=O)CC(O)=O TVOIPJPTFTYKQM-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229940061374 relenza Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 230000024275 uncoating of virus Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 208000028110 viral sexually transmitted disease Diseases 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 229940032912 zephiran Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- SRWMQSFFRFWREA-UHFFFAOYSA-M zinc formate Chemical compound [Zn+2].[O-]C=O SRWMQSFFRFWREA-UHFFFAOYSA-M 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229940006174 zinc valerate Drugs 0.000 description 1
- VRGNUPCISFMPEM-ZVGUSBNCSA-L zinc;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Zn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VRGNUPCISFMPEM-ZVGUSBNCSA-L 0.000 description 1
- LPEBYPDZMWMCLZ-CVBJKYQLSA-L zinc;(z)-octadec-9-enoate Chemical compound [Zn+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O LPEBYPDZMWMCLZ-CVBJKYQLSA-L 0.000 description 1
- JNPQFTCBVDSMDO-UHFFFAOYSA-L zinc;2,3-dihydroxypropanoate Chemical compound [Zn+2].OCC(O)C([O-])=O.OCC(O)C([O-])=O JNPQFTCBVDSMDO-UHFFFAOYSA-L 0.000 description 1
- MCOGTQGPHPAUJN-UHFFFAOYSA-L zinc;2-hydroxyacetate Chemical compound [Zn+2].OCC([O-])=O.OCC([O-])=O MCOGTQGPHPAUJN-UHFFFAOYSA-L 0.000 description 1
- UBRKSSSORHJPQI-UHFFFAOYSA-L zinc;2-oxopropanoate Chemical compound [Zn+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UBRKSSSORHJPQI-UHFFFAOYSA-L 0.000 description 1
- AGFGXVAAIXIOFZ-UHFFFAOYSA-L zinc;butanedioate Chemical compound [Zn+2].[O-]C(=O)CCC([O-])=O AGFGXVAAIXIOFZ-UHFFFAOYSA-L 0.000 description 1
- WDHVIZKSFZNHJB-UHFFFAOYSA-L zinc;butanoate Chemical compound [Zn+2].CCCC([O-])=O.CCCC([O-])=O WDHVIZKSFZNHJB-UHFFFAOYSA-L 0.000 description 1
- JDLYKQWJXAQNNS-UHFFFAOYSA-L zinc;dibenzoate Chemical compound [Zn+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 JDLYKQWJXAQNNS-UHFFFAOYSA-L 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- BUDAIZWUWHWZPQ-UHFFFAOYSA-L zinc;pentanoate Chemical compound [Zn+2].CCCCC([O-])=O.CCCCC([O-])=O BUDAIZWUWHWZPQ-UHFFFAOYSA-L 0.000 description 1
- XDWXRAYGALQIFG-UHFFFAOYSA-L zinc;propanoate Chemical compound [Zn+2].CCC([O-])=O.CCC([O-])=O XDWXRAYGALQIFG-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52884303P | 2003-12-10 | 2003-12-10 | |
| US11/003,302 US7968122B2 (en) | 2003-12-10 | 2004-12-03 | Anti-viral pharmaceutical compositions |
| PCT/US2004/041117 WO2005074947A2 (en) | 2003-12-10 | 2004-12-08 | Anti-viral pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007513959A true JP2007513959A (ja) | 2007-05-31 |
| JP2007513959A5 JP2007513959A5 (https=) | 2008-02-07 |
Family
ID=34840339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006543955A Pending JP2007513959A (ja) | 2003-12-10 | 2004-12-08 | 抗ウイルス性薬学的組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7968122B2 (https=) |
| EP (1) | EP1706122B1 (https=) |
| JP (1) | JP2007513959A (https=) |
| KR (1) | KR20060118573A (https=) |
| AT (1) | ATE415166T1 (https=) |
| AU (1) | AU2004315262A1 (https=) |
| BR (1) | BRPI0417559A (https=) |
| CA (1) | CA2549083A1 (https=) |
| DE (1) | DE602004018032D1 (https=) |
| DK (1) | DK1706122T3 (https=) |
| EA (1) | EA200601124A1 (https=) |
| IL (1) | IL176161A0 (https=) |
| MA (1) | MA28334A1 (https=) |
| MX (1) | MXPA06006650A (https=) |
| NO (1) | NO20063147L (https=) |
| WO (1) | WO2005074947A2 (https=) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011515391A (ja) * | 2008-03-20 | 2011-05-19 | クリステル・タノ | 普通感冒の治療用の医薬の製造における物質の使用 |
| JP2011246476A (ja) * | 2006-09-21 | 2011-12-08 | Alcon Research Ltd | 自己保存型水性医薬組成物 |
| JP2012526857A (ja) * | 2009-05-16 | 2012-11-01 | トルテック コーポレーション | 静電的に帯電した多作用性経鼻適用、製品及び方法 |
| WO2013005446A1 (ja) * | 2011-07-06 | 2013-01-10 | 株式会社Ｎｂｃメッシュテック | 抗ウイルス性樹脂部材 |
| JPWO2011142484A1 (ja) * | 2010-05-14 | 2013-07-22 | 株式会社日本触媒 | ポリアルキレンイミンを含むウイルス感染症治療薬 |
| WO2015072125A1 (ja) * | 2013-11-14 | 2015-05-21 | 日本曹達株式会社 | 抗パルボウイルス組成物 |
| JP2015520755A (ja) * | 2012-05-18 | 2015-07-23 | ウニヴェルスィテット ヤギエルロンスキ | コロナウイルスに起因する感染の治療及び予防におけるキトサンポリマーの使用 |
| JP2016216415A (ja) * | 2015-05-25 | 2016-12-22 | ロート製薬株式会社 | 爪用組成物 |
| JP2017518347A (ja) * | 2014-06-18 | 2017-07-06 | メダ ウーテーセー アクティエボラーグ | 経口組成物 |
| JP2022124689A (ja) * | 2021-02-16 | 2022-08-26 | 住友ベークライト株式会社 | 多層フィルム及び包装体 |
| JP2022157406A (ja) * | 2021-03-31 | 2022-10-14 | 独立行政法人国立高等専門学校機構 | ウイルス不活化構造 |
| WO2022219944A1 (ja) * | 2021-04-16 | 2022-10-20 | 株式会社日本触媒 | 抗コロナウイルス剤 |
| JP2023522049A (ja) * | 2020-04-15 | 2023-05-26 | ソリープラス ゲーエムベーハー | 感染を防止および処置する手段および方法 |
| JP2023531854A (ja) * | 2020-04-14 | 2023-07-26 | ヴェクター ヴィターレ アイピー エルエルシー | ウイルス感染を予防または処置する方法 |
| JP2023535554A (ja) * | 2020-06-30 | 2023-08-18 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | 消毒組成物 |
| JP2023538449A (ja) * | 2020-08-24 | 2023-09-07 | ナノメリクス リミテッド | ウイルス阻害剤 |
| WO2024135675A1 (ja) * | 2022-12-22 | 2024-06-27 | サンスター株式会社 | 抗インフルエンザウイルス用咽喉用組成物、及び咽喉用抗インフルエンザウイルス剤 |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090012174A1 (en) * | 2004-12-09 | 2009-01-08 | The Dial Corporation | Compositions Having a High Antiviral and Antibacterial Efficacy |
| CA2588802A1 (en) * | 2004-12-09 | 2006-06-15 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
| CN101384171A (zh) * | 2004-12-09 | 2009-03-11 | 日晷公司 | 具有高抗病毒和抗菌效力的组合物 |
| MX2007006860A (es) * | 2004-12-09 | 2008-02-15 | Dial Corp | Composiciones que tienen alta eficacia antiviral y antibacterial. |
| WO2006062846A2 (en) * | 2004-12-09 | 2006-06-15 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
| WO2007024973A1 (en) * | 2005-08-22 | 2007-03-01 | Quick-Med Technologies, Inc. | Disinfectant with quaternary ammonium polymers and copolymers |
| US20080000473A1 (en) * | 2005-12-29 | 2008-01-03 | Hugo Stephenson | pH-Based Methods and Devices for Preventing Hemagglutinin Cell Membrane Fusion |
| WO2007112966A1 (en) * | 2006-04-04 | 2007-10-11 | Marinomed Biotechnologie Gmbh | Cellulose sulfate for the treatment of rhinovirus infection |
| EP1842546B1 (en) * | 2006-04-04 | 2009-03-11 | Marinomed Biotechnologie GmbH | Cellulose sulfate for the treatment of rhinovirus infection |
| US20090238883A1 (en) * | 2006-04-28 | 2009-09-24 | Kren Betsy T | Liver-specific nanocapsules and methods of using |
| US20070274926A1 (en) * | 2006-05-26 | 2007-11-29 | The Dial Corporation | Method of inhibiting the transmission of viruses |
| CA2653380A1 (en) * | 2006-05-30 | 2007-12-13 | The Dial Corporation | Compositions having a high antiviral efficacy |
| CA2653347A1 (en) * | 2006-05-31 | 2007-12-13 | The Dial Corporation | Alcohol-containing antimicrobial compositions having improved efficacy |
| CA2654079A1 (en) | 2006-06-02 | 2008-03-27 | The Dial Corporation | Method of inhibiting the transmission of influenza virus |
| US20080145390A1 (en) * | 2006-06-05 | 2008-06-19 | The Dial Corporation | Methods and articles having a high antiviral and antibacterial efficacy |
| DE102006033167A1 (de) * | 2006-07-10 | 2008-01-24 | Gelita Ag | Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers |
| WO2008042891A2 (en) * | 2006-10-02 | 2008-04-10 | Oregan Biomedical Engineering Institute, Inc. | Chitosan ophthalmic devices and methods |
| WO2008157514A2 (en) * | 2007-06-14 | 2008-12-24 | Genesegues, Inc. | Metal ion-treated biocompatible polymers useful for nanoparticles |
| EP2361084B1 (en) * | 2008-07-07 | 2017-03-01 | Trutek Corp. | Electrostatically charged multi-acting nasal application, product, and method |
| GB2521488A (en) | 2011-10-31 | 2015-06-24 | Premiere Polish Company Ltd | Personal care composition and a device for dispensing the same |
| EP2846773A4 (en) | 2012-05-10 | 2015-12-30 | Painreform Ltd | DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF |
| US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
| US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
| US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
| US20150018760A1 (en) * | 2013-07-11 | 2015-01-15 | Kathryn Morton HARDIN | Nasal irrigation solution preparation system and method of preparation |
| US9192692B2 (en) | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan stenting paste |
| US9192574B2 (en) | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan paste wound dressing |
| CA2959660A1 (en) | 2014-09-03 | 2016-03-10 | Genesegues, Inc. | Therapeutic nanoparticles and related compositions, methods, and systems |
| AR100459A1 (es) * | 2015-05-15 | 2016-10-05 | Química Luar S R L | Una composición farmacéutica antiviral de uso tópico |
| WO2017019010A1 (en) * | 2015-07-27 | 2017-02-02 | Kimberly-Clark Worldwide, Inc. | Disinfectant composition with rapid antiviral efficacy |
| US10293012B2 (en) | 2017-05-04 | 2019-05-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of using extracts of melissa officinalis against filoviruses |
| WO2018208739A1 (en) * | 2017-05-08 | 2018-11-15 | Thomas Cahill | Pharmaceutical compositions comprising caffeic acid chelates |
| WO2020005841A1 (en) | 2018-06-25 | 2020-01-02 | Triumph Pharmaceuticals Inc. | Methods of inhibiting microbial infections using zinc-containing compositions |
| US11369578B2 (en) * | 2018-11-15 | 2022-06-28 | Bluewillow Biologics, Inc. | Persistent topical antimicrobial compositions and methods of using the same |
| CN114732822B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| EP3888629A1 (en) * | 2020-03-31 | 2021-10-06 | Dr. Kurt Wolff GmbH & Co. KG | Composition for treatment or prevention of a virus infection |
| WO2021209493A2 (en) * | 2020-04-15 | 2021-10-21 | Solyplus Gmbh | Means and methods of preventing and treating infections |
| US20210330698A1 (en) * | 2020-04-23 | 2021-10-28 | Johnson & Johnson Consumer Inc. | Methods and compositions for inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers |
| US12186335B2 (en) | 2020-04-23 | 2025-01-07 | Johnson & Johnson Consumer Inc. | Methods and compositions for inhibiting enveloped viruses using high molecular weight hydrophobically modified alkali swellable emulsion polymers and surfactant |
| US11690869B2 (en) | 2020-04-23 | 2023-07-04 | Johnson & Johnson Consumer Inc. | Methods of inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers |
| KR102651711B1 (ko) * | 2020-04-27 | 2024-03-27 | 조석형 | 항균 및 항바이러스제, 이의 제조방법 및 이로부터 제조된 보조사료 |
| ES3024971T3 (en) * | 2020-09-24 | 2025-06-05 | Dr Kurt Wolff Gmbh & Co Kg | Hydroxyapatite composition for treatment and/or prevention of a virus infection |
| US20240050366A1 (en) * | 2020-12-22 | 2024-02-15 | Solyplus Gmbh | Means and methods of preventing, treating and detecting infections |
| WO2022185326A1 (en) * | 2021-03-03 | 2022-09-09 | Amitava Mazumder | Antiviral, anti sars-cov-2, anti h1n3, antibacterial and antimicrobial compositions and methods of preparation thereof |
| PT117220B (pt) | 2021-05-11 | 2024-07-16 | Inst Superior Tecnico | Solução desinfetante compreendendo álcool e quitosano, processo para a sua obtenção e respetivos usos |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4548950A (en) * | 1982-06-30 | 1985-10-22 | Biorex Laboratories Limited | Pharmaceutical composition |
| US4661354A (en) * | 1984-06-21 | 1987-04-28 | Finnerty Edmund F | Topical treatment of herpes simplex with a zinc sulfate-camphor water solution |
| JPH05124955A (ja) * | 1991-10-30 | 1993-05-21 | Shiseido Co Ltd | 噴霧用ゲル基剤およびそれを用いた噴霧用点鼻剤 |
| WO1995028158A1 (en) * | 1994-04-13 | 1995-10-26 | Janssen Pharmaceutica N.V. | Intranasal antimigraine composition |
| EP0692253A1 (en) * | 1992-08-07 | 1996-01-17 | Nippon Soda Co., Ltd. | Prophylatic for domestic animal mastitis |
| US5798391A (en) * | 1994-01-24 | 1998-08-25 | Aromafarm Limited | Injectable solution of benzalkonium fluoride |
| WO2000015192A1 (en) * | 1998-09-17 | 2000-03-23 | Zonagen, Inc. | Methods and materials related to bioadhesive contraceptive gels |
| JP2001271098A (ja) * | 2000-03-24 | 2001-10-02 | Lion Corp | 電解洗浄水及びその製造方法、並びに、その電解洗浄水を用いる衣類又は食器の洗浄システム |
| WO2002067831A1 (en) * | 2001-02-16 | 2002-09-06 | Fust Charles A | Composition for freshening nostrils and sinus cavities |
| WO2003060003A1 (en) * | 2001-12-21 | 2003-07-24 | E.I. Du Pont De Nemours And Company | Antimicrobial solid surface materials containing chitosan-metal complexes |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3404987A (en) * | 1965-03-31 | 1968-10-08 | Procter & Gamble | Food preservative compositions and method for inhibiting microbial growth in food products |
| LU77562A1 (de) | 1977-06-17 | 1979-03-26 | Ciba Geigy Ag | Verfahren zur herstellung von neuen pharmazeutischen praeparaten |
| EP0012115A1 (de) | 1978-12-04 | 1980-06-11 | Ciba-Geigy Ag | Pharmazeutische Präparate zur topischen Behandlung von Virusinfektionen |
| US4503070A (en) | 1981-07-31 | 1985-03-05 | Eby Iii George A | Method for reducing the duration of the common cold |
| US4956385A (en) | 1981-07-31 | 1990-09-11 | Eby Iii George A | Method for reducing the duration of the common cold |
| EP0285357A3 (en) | 1987-03-31 | 1989-10-25 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Control of retroviruses |
| GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| US6321750B1 (en) | 1993-05-03 | 2001-11-27 | Patrick D. Kelly | Condom lubricants with zinc salts as anti-viral additives |
| SE518597C2 (sv) | 1994-05-04 | 2002-10-29 | Medicarb Ab | Användning av kitosan i kombination med en sulfaterad, negativt laddad polysackarid för framställning av en dentalt verksam munhygienkomposition för behandling av parodontit, plaques och/eller karies |
| NL9500216A (nl) | 1995-02-06 | 1996-09-02 | Bio Pharma Sciences Bv | Farmaceutische samenstelling voor de behandeling van herpes. |
| JP3837769B2 (ja) | 1995-06-12 | 2006-10-25 | 大塚製薬株式会社 | 抗ウイルス剤 |
| GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| SE507028C2 (sv) | 1996-08-06 | 1998-03-16 | Medicarb Ab | Ny medicinsk användning |
| SE508760C2 (sv) | 1997-04-29 | 1998-11-02 | Medicarb Ab | Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur |
| TW546151B (en) * | 1997-07-23 | 2003-08-11 | Senju Pharma Co | Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| US20020022660A1 (en) * | 1998-01-20 | 2002-02-21 | Hanuman B. Jampani | Deep penetrating antimicrobial compositions |
| DE19818842C1 (de) | 1998-04-28 | 2000-01-05 | Suedzucker Ag | Erkältungsmittel |
| US6080783A (en) | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
| US6231889B1 (en) | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
| US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6423329B1 (en) * | 1999-02-12 | 2002-07-23 | The Procter & Gamble Company | Skin sanitizing compositions |
| US20020151521A1 (en) | 1999-03-30 | 2002-10-17 | Burke Peter A. | Universal antiviral composition |
| US6570054B1 (en) | 1999-05-21 | 2003-05-27 | The Procter & Gamble Company | Absorbent article having a stable skin care composition |
| US20040033260A1 (en) * | 1999-10-19 | 2004-02-19 | The Procter & Gamble Company | Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
| FR2801601B1 (fr) * | 1999-11-26 | 2003-04-25 | Rhodia Chimie Sa | Complexe silicone reticulable thermiquement / adhesif dont l'interface possede une force de decollement modulable |
| US20030206958A1 (en) | 2000-12-22 | 2003-11-06 | Cattaneo Maurizio V. | Chitosan biopolymer for the topical delivery of active agents |
| US6638915B1 (en) | 2000-06-30 | 2003-10-28 | Harold Killam | Anti-viral composition |
| US20020136768A1 (en) | 2000-11-14 | 2002-09-26 | Staats Victor J. | Antimicrobial composition |
| CA2433037C (en) * | 2000-12-28 | 2010-12-21 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| EP1420642A2 (en) * | 2001-07-02 | 2004-05-26 | Surecide Technologies, LLC | Novel synergistic antimicrobial compositions and methods |
| EP1480517A4 (en) | 2002-02-07 | 2007-08-22 | Univ Columbia | ZINC SALT COMPOSITIONS FOR PREVENTING MOLECULAR BREAST EXTRACTION THROUGH SPERMICIDES AND MICROBICIDES |
| AU2003274800A1 (en) | 2002-10-31 | 2004-05-25 | Lae-Ok Park | Anticancer or antiviral composition |
| WO2004080210A1 (en) | 2003-03-14 | 2004-09-23 | Boehringer Ingelheim Danmark A/S | Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea |
| CN1267102C (zh) | 2003-06-05 | 2006-08-02 | 广西半宙制药股份有限公司 | 一种具有抗病毒作用的复合物及其制备方法 |
-
2004
- 2004-12-03 US US11/003,302 patent/US7968122B2/en not_active Expired - Fee Related
- 2004-12-08 DE DE602004018032T patent/DE602004018032D1/de not_active Expired - Lifetime
- 2004-12-08 AT AT04821304T patent/ATE415166T1/de not_active IP Right Cessation
- 2004-12-08 JP JP2006543955A patent/JP2007513959A/ja active Pending
- 2004-12-08 EP EP04821304A patent/EP1706122B1/en not_active Expired - Lifetime
- 2004-12-08 CA CA002549083A patent/CA2549083A1/en not_active Abandoned
- 2004-12-08 WO PCT/US2004/041117 patent/WO2005074947A2/en not_active Ceased
- 2004-12-08 EA EA200601124A patent/EA200601124A1/ru unknown
- 2004-12-08 AU AU2004315262A patent/AU2004315262A1/en not_active Abandoned
- 2004-12-08 DK DK04821304T patent/DK1706122T3/da active
- 2004-12-08 MX MXPA06006650A patent/MXPA06006650A/es unknown
- 2004-12-08 BR BRPI0417559-0A patent/BRPI0417559A/pt not_active IP Right Cessation
- 2004-12-08 KR KR1020067013765A patent/KR20060118573A/ko not_active Abandoned
-
2006
- 2006-06-06 IL IL176161A patent/IL176161A0/en unknown
- 2006-07-06 NO NO20063147A patent/NO20063147L/no not_active Application Discontinuation
- 2006-07-07 MA MA29172A patent/MA28334A1/fr unknown
-
2011
- 2011-05-19 US US13/111,873 patent/US8470346B2/en not_active Expired - Fee Related
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4548950A (en) * | 1982-06-30 | 1985-10-22 | Biorex Laboratories Limited | Pharmaceutical composition |
| US4661354A (en) * | 1984-06-21 | 1987-04-28 | Finnerty Edmund F | Topical treatment of herpes simplex with a zinc sulfate-camphor water solution |
| JPH05124955A (ja) * | 1991-10-30 | 1993-05-21 | Shiseido Co Ltd | 噴霧用ゲル基剤およびそれを用いた噴霧用点鼻剤 |
| EP0692253A1 (en) * | 1992-08-07 | 1996-01-17 | Nippon Soda Co., Ltd. | Prophylatic for domestic animal mastitis |
| US5798391A (en) * | 1994-01-24 | 1998-08-25 | Aromafarm Limited | Injectable solution of benzalkonium fluoride |
| WO1995028158A1 (en) * | 1994-04-13 | 1995-10-26 | Janssen Pharmaceutica N.V. | Intranasal antimigraine composition |
| WO2000015192A1 (en) * | 1998-09-17 | 2000-03-23 | Zonagen, Inc. | Methods and materials related to bioadhesive contraceptive gels |
| JP2001271098A (ja) * | 2000-03-24 | 2001-10-02 | Lion Corp | 電解洗浄水及びその製造方法、並びに、その電解洗浄水を用いる衣類又は食器の洗浄システム |
| WO2002067831A1 (en) * | 2001-02-16 | 2002-09-06 | Fust Charles A | Composition for freshening nostrils and sinus cavities |
| WO2003060003A1 (en) * | 2001-12-21 | 2003-07-24 | E.I. Du Pont De Nemours And Company | Antimicrobial solid surface materials containing chitosan-metal complexes |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011246476A (ja) * | 2006-09-21 | 2011-12-08 | Alcon Research Ltd | 自己保存型水性医薬組成物 |
| JP2011515391A (ja) * | 2008-03-20 | 2011-05-19 | クリステル・タノ | 普通感冒の治療用の医薬の製造における物質の使用 |
| JP2012526857A (ja) * | 2009-05-16 | 2012-11-01 | トルテック コーポレーション | 静電的に帯電した多作用性経鼻適用、製品及び方法 |
| JPWO2011142484A1 (ja) * | 2010-05-14 | 2013-07-22 | 株式会社日本触媒 | ポリアルキレンイミンを含むウイルス感染症治療薬 |
| WO2013005446A1 (ja) * | 2011-07-06 | 2013-01-10 | 株式会社Ｎｂｃメッシュテック | 抗ウイルス性樹脂部材 |
| US9380785B2 (en) | 2011-07-06 | 2016-07-05 | Nbc Meshtec, Inc. | Antiviral resin member |
| JP2015520755A (ja) * | 2012-05-18 | 2015-07-23 | ウニヴェルスィテット ヤギエルロンスキ | コロナウイルスに起因する感染の治療及び予防におけるキトサンポリマーの使用 |
| WO2015072125A1 (ja) * | 2013-11-14 | 2015-05-21 | 日本曹達株式会社 | 抗パルボウイルス組成物 |
| JPWO2015072125A1 (ja) * | 2013-11-14 | 2017-03-16 | 日本曹達株式会社 | 抗パルボウイルス組成物 |
| JP2017518347A (ja) * | 2014-06-18 | 2017-07-06 | メダ ウーテーセー アクティエボラーグ | 経口組成物 |
| JP2016216415A (ja) * | 2015-05-25 | 2016-12-22 | ロート製薬株式会社 | 爪用組成物 |
| US12527819B2 (en) | 2020-04-14 | 2026-01-20 | Vector Vitale Ip Llc | Method of preventing or treating viral infections |
| JP7734973B2 (ja) | 2020-04-14 | 2025-09-08 | ヴェクター ヴィターレ アイピー エルエルシー | ウイルス感染を予防または処置する方法 |
| JP2023531854A (ja) * | 2020-04-14 | 2023-07-26 | ヴェクター ヴィターレ アイピー エルエルシー | ウイルス感染を予防または処置する方法 |
| JP2023522049A (ja) * | 2020-04-15 | 2023-05-26 | ソリープラス ゲーエムベーハー | 感染を防止および処置する手段および方法 |
| JP2023535554A (ja) * | 2020-06-30 | 2023-08-18 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | 消毒組成物 |
| JP2023538449A (ja) * | 2020-08-24 | 2023-09-07 | ナノメリクス リミテッド | ウイルス阻害剤 |
| JP2022124689A (ja) * | 2021-02-16 | 2022-08-26 | 住友ベークライト株式会社 | 多層フィルム及び包装体 |
| JP7664607B2 (ja) | 2021-03-31 | 2025-04-18 | 独立行政法人国立高等専門学校機構 | ウイルス不活化構造 |
| JP2022157406A (ja) * | 2021-03-31 | 2022-10-14 | 独立行政法人国立高等専門学校機構 | ウイルス不活化構造 |
| JPWO2022219944A1 (https=) * | 2021-04-16 | 2022-10-20 | ||
| WO2022219944A1 (ja) * | 2021-04-16 | 2022-10-20 | 株式会社日本触媒 | 抗コロナウイルス剤 |
| JP7627445B2 (ja) | 2021-04-16 | 2025-02-06 | 株式会社日本触媒 | 抗コロナウイルス剤 |
| WO2024135675A1 (ja) * | 2022-12-22 | 2024-06-27 | サンスター株式会社 | 抗インフルエンザウイルス用咽喉用組成物、及び咽喉用抗インフルエンザウイルス剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8470346B2 (en) | 2013-06-25 |
| US20050232895A1 (en) | 2005-10-20 |
| MA28334A1 (fr) | 2006-12-01 |
| CA2549083A1 (en) | 2005-08-18 |
| DK1706122T3 (da) | 2009-03-23 |
| ATE415166T1 (de) | 2008-12-15 |
| DE602004018032D1 (de) | 2009-01-08 |
| EP1706122B1 (en) | 2008-11-26 |
| EP1706122A2 (en) | 2006-10-04 |
| NO20063147L (no) | 2006-09-08 |
| US7968122B2 (en) | 2011-06-28 |
| EA200601124A1 (ru) | 2006-12-29 |
| MXPA06006650A (es) | 2007-01-26 |
| KR20060118573A (ko) | 2006-11-23 |
| WO2005074947A2 (en) | 2005-08-18 |
| US20110223259A1 (en) | 2011-09-15 |
| AU2004315262A1 (en) | 2005-08-18 |
| IL176161A0 (en) | 2006-10-05 |
| WO2005074947A3 (en) | 2005-09-22 |
| BRPI0417559A (pt) | 2007-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7968122B2 (en) | Anti-viral pharmaceutical compositions | |
| SK153398A3 (en) | Antimicrobial composition and its use for the preparation of product for treatment of diseases induced by herpex simplex virus and other infectious diseases | |
| AU2020203720B2 (en) | Combination product for the prevention of sexually transmitted infections | |
| US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
| US20260007596A1 (en) | Compositions for preventing infection | |
| JP2002515410A (ja) | 広域スペクトルの殺菌用及び殺精子用の組成物、装置、及び方法 | |
| JP2018535249A (ja) | ランピルナーゼおよび／またはアンフィナーゼを使用するウイルス性結膜炎の処置 | |
| TWI829785B (zh) | 流感病毒複製抑制劑之組合 | |
| CN116473911A (zh) | 鼻用聚维酮碘凝胶制剂及其制备方法和应用 | |
| JPH11193242A (ja) | 抗インフルエンザウイルス剤 | |
| EP4710930A1 (en) | Anti-influenza virus composition containing xanthan gum or fucoidan | |
| Liang et al. | In vitro Inactivation of SARS-Cov-2 by Povidone-Iodine In situ Gel Forming Solution | |
| TR2022020608A2 (tr) | Anti̇vi̇ral burun spreyi̇ | |
| JP2020510703A (ja) | 哺乳類の皮膚および粘膜の単純ヘルペス症状の治療 | |
| HK40028689A (en) | Treatment of herpes simplex symptoms on skin and mucous membrane of mammals | |
| US20090270472A1 (en) | Method to use oxymetazoline to interrupt the development of the common cold syndrome | |
| HK1102704A (en) | Anti-viral pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110223 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110803 Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110803 |